ログイン 会員登録
icon_bulk_order一括注文 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: ホーム > TFPI

TFPI

概要

Name:Tissue factor pathway inhibitor
Target Synonym:TFPI,Tissue Factor Pathway Inhibitor,Extrinsic Pathway Inhibitor,TFPI1,LACI,EPI,Anti-Convertin,TFI,Lipoprotein-associated coagulation inhibitor,Tissue Factor Pathway Inhibitor (Lipoprotein-Associated Coagulation Inhibitor)
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

製品リスト製品比較と製品注文

製品仕様別:
製品カテゴリー別:
種類別:
タグ別:
コンジュゲート:
製造番号 種類 製品説明 構造 純度 特徴
TFI-H8226 Human Biotinylated Human TFPI Protein, His Tag, ultra sensitivity (primary amine labeling)
TFI-H8226-structure
TFI-H8226-sds
TFI-H5226 Human Human TFPI Protein, His Tag (active enzyme)
TFI-H5226-structure
TFI-H5226-sds
ACRO Quality

Synonym Name

TFPI,LACI,TFPI1,EPI,TFI

Background

Tissue factor pathway inhibitor (TFPI) is also known as Extrinsic pathway inhibitor (EPI), Lipoprotein - associated coagulation inhibitor (LACI), is a plasma proteinase inhibitor synthesized by vascular endothelial cells and part of it is associated with glycosaminoglycans of these cells. TFPI is a single-chain polypeptide which can reversibly inhibit Factor Xa (Xa) and Thrombin (Factor IIa). TFPI is a secreted protein with a N­terminal acidic region, three Kunitz (K) domains separated with by two linker regions, and a C­terminal basic region. The first K domain inhibits coagulation factor VIIa complexed to tissue factor (TF); The second K domain inhibits factor Xa; The third K domain binds to heparin; The C­terminal basic region may have several functions. For example, it plays an important role in binding of TFPI to cell surfaces.

Clinical and Translational Updates

公開薬物情報

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Concizumab NNC-0172-2021; NNC-172-2021; mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021 Approved Novo Nordisk A/S Alhemo Japan Hemophilia A; Hemophilia B Novo Nordisk Pharma Ltd 2023-09-25 Hemophilia A; Hemophilia B; Hemorrhage Details

臨床試験情報

Name Research Code Research Phase Company Indications Clinical Trials
MG-1113 MG-1113 Phase 1 Clinical GC Biopharma Corp Hemophilia A Details
KN-057 KN-057 Phase 3 Clinical Suzhou Alphamab Co Ltd Hemophilia A; Hemophilia B Details
Befovacimab BAY-109; BAY-1093884 Phase 1 Clinical Morphosys Ag, Bayer AG Hemophilia A; Hemophilia B Details
AP-017 AP017; AP-017 Phase 1 Clinical Anyuan Pharmaceutical Technology (Shanghai) Co Ltd Hemophilia A; Hemophilia B Details

This web search service is supported by Google Inc.

totopphone